Pharmaceutical packaging has undergone a tremendous shift in the market preference. Now, there is a preference for pharma glass over plastics. This trend has been especially true in the injectable devices segment. This shift has also affected the product portfolio of a number of renowned parenteral packaging supplier companies in their struggle to meet market demand.
A number of tests were conducted in pilot plants to assess the feasibility of making the change from glass to plastic.
- Recent advancements in the drug formulation stage have resulted in increased drug complexity as well as quality challenges that arise due to the use of glass. This includes delamination, breakage as well as siliconization, among a host of other factors. Therefore, the problems posed by glass have also affected pharma players’ injectable drug’s packaging procurement. Why so? It is because the supply base is characterized by long term contracts.
However, it is vital to note that parenteral packaging is also essential. Industrial agitators also play a vital role.
Drugs are most often than not administered through intravenous, intra ocular or intradermal formats. These are called parenteral drugs. These drugs differ from extra dermal and conventional oral drug intake. Parenteral drugs help in curing diseases like cancer, diabetes and rheumatoid arthritis, in addition to a host of other diseases. Therefore, as far as these diseases are concerned, injectable are highly effective methods of administration. Therefore, experts are testing the effectiveness of plastic over glass. The incorporation of industrial agitators is also novel.
It is pertinent to mention that parenteral packaging is among the fastest growing pharmaceutical packaging formats. From 2014-19, parenteral package had a CAGR of 8-9%. The spike in demand is driven by the rise in lifestyle disease, increasing health awareness and an ageing population in countries like China and India.
No comments:
Post a Comment